These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 7107397)

  • 21. Enhancement of the effect of cytotoxic drugs by radiosensitizers.
    Martin WM; McNally NJ; De Ronde J
    Br J Cancer; 1981 Jun; 43(6):756-66. PubMed ID: 7248157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanism of melphalan crosslink enhancement by misonidazole pretreatment.
    Taylor YC; Sawyer JM; Hsu B; Brown JM
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1603-7. PubMed ID: 6480448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of the nitroimidazole Ro 03-8799 on the activity of chemotherapeutic agents against a murine tumour in vivo.
    Sheldon PW; Gibson P
    Br J Cancer; 1984 Mar; 49(3):291-300. PubMed ID: 6704303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors influencing the chemosensitization of melphalan by misonidazole.
    Randhawa VS; Stewart FA; Denekamp J; Stratford MR
    Br J Cancer; 1985 Feb; 51(2):219-28. PubMed ID: 3966979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potentiation of melphalan activity in the KHT sarcoma by the radiosensitizer RSU 1069.
    Siemann DW; Maddison K; Wolf K
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1657-60. PubMed ID: 6548212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Enhancement of MeCCNU potency (chemosensitization) by misonidazole in a human melanoma xenograft system].
    Osieka R; Glatte P; Haedecke U; Schmidt CG
    Strahlentherapie; 1982 Oct; 158(10):620-9. PubMed ID: 7179344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemopotentiation in vivo: no loss of sensitization with fractionation.
    Hill SA; Siemann DW
    Br J Cancer; 1984 Oct; 50(4):509-17. PubMed ID: 6487517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain.
    Hirst DG; Brown JM; Hazlehurst JL
    Br J Cancer; 1982 Jul; 46(1):109-16. PubMed ID: 7201845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancing effect of misonidazole on the response of the RIF-1 tumour to cyclophosphamide.
    Law MP; Hirst DG; Brown JM
    Br J Cancer; 1981 Aug; 44(2):208-18. PubMed ID: 7272187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemosensitization by lipophilic nitroimidazoles.
    Twentyman PR; Workman P
    Br J Cancer; 1983 Jul; 48(1):17-26. PubMed ID: 6871076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Growth delay in small EMT6 spheroids induced by cytotoxic drugs and its modification by misonidazole pretreatment under hypoxic conditions.
    Twentyman PR
    Br J Cancer; 1982 Apr; 45(4):565-70. PubMed ID: 7073947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The advantageous use of hypoxic tumour cells in cancer therapy: identical chemosensitization by metronidazole and misonidazole at moderately elevated temperatures.
    Urano M; Wong KH; Reynolds R; Begley J
    Int J Hyperthermia; 1995; 11(3):379-88. PubMed ID: 7636324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancement of chemotherapy and nitroimidazole-induced chemopotentiation by the vasoactive agent hydralazine.
    Siemann DW
    Br J Cancer; 1990 Sep; 62(3):348-53. PubMed ID: 2206941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Altered pharmacokinetics in the mechanism of chemosensitization: effects of nitroimidazoles and other chemical modifiers on the pharmacokinetics, antitumour activity and acute toxicity of selected nitrogen mustards.
    Lee FY; Workman P
    Cancer Chemother Pharmacol; 1986; 17(1):30-7. PubMed ID: 3698174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Misonidazole hypoxic cytotoxicity and chemosensitization in two cell lines with different intracellular glutathione levels.
    DeGraff WG; Russo A; Friedman N; Mitchell JB
    Eur J Cancer; 1990 Jan; 26(1):17-20. PubMed ID: 2138473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro pre-incubation with misonidazole under hypoxic conditions--effect on drug response of EMT6 spheroids.
    Twentyman PR
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):607-9. PubMed ID: 7107381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Misonidazole chemosensitization of EMT6 spheroids to melphalan.
    Horsman MR; Wood PJ; Brown JM
    Radiother Oncol; 1989 May; 15(1):103-14. PubMed ID: 2748937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of misonidazole on the cytotoxicity and DNA cross-linking activity of an activated sulfidocyclophosphamide in hypoxic mouse leukemia cells.
    Ramonas LM; Erickson LC; McManus ME
    Mol Pharmacol; 1982 Jul; 22(1):175-81. PubMed ID: 7121448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancement of the DNA cross-linking activity of melphalan by misonidazole in vivo.
    Murray D; Meyn RE
    Br J Cancer; 1983 Feb; 47(2):195-203. PubMed ID: 6824567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazole.
    Clement JJ; Gorman MS; Wodinsky I; Catane R; Johnson RK
    Cancer Res; 1980 Nov; 40(11):4165-72. PubMed ID: 7471058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.